Contraline Secures $92.5M to Push Its Male Birth Control Candidates Forward
Contraline raised $92.5 million in new funding to advance its two male contraceptive candidates, including a once-daily topical gel and an implantable option.
Contraline raised $92.5 million in new funding to advance its two male contraceptive candidates, including a once-daily topical gel and an implantable option.
Ilant Health's Series A round was led by Cornucopian Capital, with participation from naturalX, Peakbridge, Semcap AI, Evidenced, Operator Partners, Celtic, LifeX and AlphaLab.
Garner's Series E round was led by Index Ventures with participation from Kleiner Perkins, Redpoint, Thrive, Sequoia, Founders Fund and Kaiser Permanente Ventures.
Capital is flowing into the broader women’s health ecosystem at a pace we have not seen before. The practices that will capture value from that momentum are the ones that get their operational house in order now.
Anomaly's $17 million round was led by Sound Ventures and included participation from Alumni Ventures, Link Ventures, Redesign Health and RRE Ventures.
Coral Care's Series A round was led by Haymaker Ventures, with participation from FCA Ventures, Peterson Ventures, Alleycorp, Reach Capital, Jefferson River Capital, Greymatter Capital, Mother Ventures and Charge Ventures.
Daffodil’s Series A round was led by Flare Capital Partners, with participation from LRVHealth and Maverick Ventures.
Valerie Health's financing was led by Redpoint Ventures and included participation from General Catalyst, Primary VC, BoxGroup, Karman Ventures, .406 Ventures and Waybury Capital.
With closures accelerating and communities already losing access to care, the countdown to FY 2026 is not far off. States, providers and technology partners that act now will define the future of rural health for decades; those that delay may leave billions untapped and lives at risk.
ŌURA's $900 million in funding was led by Fidelity Management & Research Company and included participation from ICONIQ, Whale Rock and Atreides.
Visana Health's Series A round was led by Noro-Moseley Partners and included participation from The Cigna Group Ventures, Intermountain Ventures, Flare Capital Partners and Frist Cressey Ventures.
Thyme Care's Series D round included participation from CVS Health Ventures, Foresite Capital, Morgan Health and Humana. In total, it has raised $275 million.
Seven Starling's $8 million raise was led by Rethink Impact and included participation from Pear VC, Zeal Capital Partners, Magnify Ventures, Ulu Ventures, Expa, Fiore Ventures, the March of Dimes, Rogue Women's Fund and Graham & Walker.
Harbor Health's funding was co-led by General Catalyst, 8VC and Alta Partners. The round also includes participation from Dell Family Office Management, Health 2047 Capital Partners, Lemhi Ventures, Martin Ventures and Breyer Capital.
Goodpath’s Series A round was led by MassMutual Ventures and included participation from Healthy Ventures. In total, the company has raised $22 million.